| abstract |
The pharmaceutical composition comprises at least one estrogenic compound, the composition is adapted as a unit dose administration on the vulva surface and has at least one non-lipid internal phase and bioadhesiveness on the vulva surface Including at least one estrogenic compound, wherein the at least one estrogenic compound is present as an equivalent of about 5 to about 1000 μg estradiol per unit dose of the composition, and is about 3 hours to about 30 when the composition is administered to the vulva surface. The at least one estrogenic compound is released daily. The composition is useful, for example, for vulva administration for the treatment of atrophic vaginitis or related diseases in menopausal or postmenopausal women. A method of treating a urogenital hypoestrogen-related disease in a female patient includes administering intravaginally at least one estrogen compound according to a therapeutic regimen, wherein the therapeutic dosage regimen includes a stepwise approach to the at least one estrogen compound. A series of compositions that release an increasing daily dose is administered for at least about one month. |